W. Lichtenegger

发表

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

A. Reles, A. Schmider, M. Press, 2005, Journal of Cancer Research and Clinical Oncology.

Risk Perception and Psychological Strain in Women with a Family History of Breast Cancer

W. Lichtenegger, S. Paepke, C. Neise, 2001, Oncology Research and Treatment.

Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking

W. Lichtenegger, J. Sehouli, J. Schefold, 2011, Annals of Surgical Oncology.

Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma

Steffen Hauptmann, Carsten Denkert, Manfred Dietel, 2002, International journal of cancer.

Incidence of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients at primary diagnosis-A potential tool for risk stratification.

M. Beckmann, H. Sommer, K. Pantel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study

W. Lichtenegger, J. Sehouli, D. Stengel, 2010, Supportive Care in Cancer.

Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer

C. Denkert, A. Reles, W. Lichtenegger, 2006, Journal of Cancer Research and Clinical Oncology.

The German SUCCESS C Study – The First European Lifestyle Study on Breast Cancer

M. Beckmann, H. Sommer, H. Hauner, 2010, Breast Care.

Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses

A. Reles, W. Lichtenegger, U. Wein, 1997, Journal of clinical ultrasound : JCU.

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

H. Sommer, W. Lichtenegger, J. Sehouli, 2013, Cancer Chemotherapy and Pharmacology.

Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study

P. Wust, J. Gellermann, W. Lichtenegger, 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.

S. Kümmel, W. Lichtenegger, J. Sehouli, 2011, Anticancer research.

Prognostic significance of angiogenic factors in uterine cervical cancer.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2011, Anticancer research.

Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients

M. Beckmann, A. Schneeweiss, H. Sommer, 2010 .

Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

W. Lichtenegger, G. Schaller, S. Coupland, 2003, Breast Cancer Research and Treatment.

Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2014, Anticancer research.

Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2009, Thrombosis research.

Long-term effects of neovaginal reconstruction with sigmoid loop technique on sexual function and self image in patients with gynecologic malignancies: results of a prospective study.

U. Neumann, W. Lichtenegger, J. Sehouli, 2008, Gynecologic oncology.

Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients.

F. Opri, W. Friedmann, W. Lichtenegger, 2004, Anticancer research.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

U. Neumann, W. Lichtenegger, J. Sehouli, 2008, Anticancer research.

Preoperative transvaginal ultrasound (TVS) in the description of pelvic tumor spread in endometrial cancer: results of a prospective study.

C. Denkert, W. Henrich, C. Wolf, 2008, Anticancer research.

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.

R. Kimmig, V. Budach, A. Hinke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative therapy modalities for cervical carcinoma.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2006, Anticancer research.

Abstract P4-11-21: Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study

M. Rezai, M. Beckmann, P. Fasching, 2015 .

Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2012, European journal of cancer.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

H. Sommer, W. Lichtenegger, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.

H. Sommer, W. Lichtenegger, J. Sehouli, 2010, Gynecologic oncology.

Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.

W. Lichtenegger, J. Sehouli, E. Braicu, 2008, Cytokine.

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

J. Blohmer, W. Lichtenegger, J. Sehouli, 2004, Oncology Research and Treatment.

A new therapeutical approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first‐line chemotherapy with paclitaxel and platinum

J. Blohmer, W. Lichtenegger, J. Sehouli, 2003, The journal of obstetrics and gynaecology research.

Predictive factors in relapsed ovarian cancer for complete tumor resection.

P. Neuhaus, W. Lichtenegger, J. Sehouli, 2011, Anticancer research.

Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study.

W. Lichtenegger, J. Sehouli, E. Braicu, 2009, Cytokine.

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial

M. Rezai, M. Beckmann, P. Fasching, 2016, BMC Cancer.

HER2 in brain metastases: issues of concordance, survival, and treatment.

W. Lichtenegger, G. Stoltenburg‐Didinger, B. Heine, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

E. Dahl, I. Klaman, W. Lichtenegger, 2006, Neoplasia.

Long‐term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies

U. Neumann, W. Lichtenegger, J. Sehouli, 2010, Journal of surgical oncology.

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.

J. Blohmer, H. Riess, W. Lichtenegger, 2002, Gynecologic oncology.

Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2010, International Journal of Gynecologic Cancer.

Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.

C. Denkert, W. Lichtenegger, J. Sehouli, 2006, Anticancer research.

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients

M. Beckmann, P. Fasching, A. Schneeweiss, 2016, Tumor Biology.

Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial

M. Beckmann, A. Schneeweiss, H. Sommer, 2008 .

Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.

W. Lichtenegger, T. Heinze, P. Schürenkämper, 1997, Anticancer research.

Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial

R. Kreienberg, H. Sommer, S. Kümmel, 2009, Cancer Chemotherapy and Pharmacology.

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

J. Blohmer, W. Lichtenegger, J. Sehouli, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.

S. Kuemmel, H. Sommer, J. Blohmer, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Boeck sarcoidosis of the breast: mammographic, ultrasound, and MR findings.

N. Hosten, R. Felix, W. Lichtenegger, 1997, Journal of computer assisted tomography.

Treatment of Gynecological Carcinomas with Campto®

J. Blohmer, W. Lichtenegger, 2000, Oncology Research and Treatment.

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO

W. Lichtenegger, J. Sehouli, G. Gebauer, 2007, Cancer Chemotherapy and Pharmacology.

Urodynamics following radical abdominal hysterectomy for cervical cancer

W. Lichtenegger, G. Ralph, K. Tamussino, 2004, Archives of Gynecology and Obstetrics.

Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.

W. Lichtenegger, J. Sehouli, K. Bühling, 2009, Anticancer research.

Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status.

W. Lichtenegger, J. Sehouli, J. Schefold, 2010, European journal of obstetrics, gynecology, and reproductive biology.

Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies".

S. Darb-Esfahani, W. Lichtenegger, J. Sehouli, 2010, Anticancer research.

Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany

W. Kuehn, W. Lichtenegger, J. Sehouli, 2009, British Journal of Cancer.

Management von Borderlinetumoren des Ovars (BOT)

C. Denkert, M. Dietel, W. Lichtenegger, 2005, Der Onkologe.

The importance of parametrial lymph nodes in the treatment of cervical cancer.

W. Lichtenegger, K. Tamussino, J. Haas, 1989 .

Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer.

S. Kuemmel, J. Blohmer, W. Lichtenegger, 2009, Anticancer research.

Pre-operative staging of cervical cancer: comparison of magnetic resonance imaging (MRI) and computed tomography (CT) with histologic results.

M. Gutberlet, P. Wust, J. Blohmer, 2000, Zentralblatt fur Gynakologie.

Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients

P. Neuhaus, W. Lichtenegger, J. Sehouli, 2010, Journal of surgical oncology.

Risk perception and anxiety of women with familial breast cancer history

J. Blohmer, W. Lichtenegger, S. Paepke, 1999 .

Amniotic Fluid Glucose Values in Normal and Abnormal Pregnancies

W. Lichtenegger, P. A. Weiss, H. Hofmann, 1985, Obstetrics and gynecology.

The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer.

T. Heusner, J. Blohmer, S. Kümmel, 2011, Anticancer research.

Internal jugular vein thrombosis caused by resistance to activated protein C as a complication of ovarian hyperstimulation after in-vitro fertilization.

H. Riess, W. Lichtenegger, H. Kentenich, 1996, Human reproduction.

Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: Results of the German SUCCESS trial.

M. Rezai, M. Beckmann, H. Tesch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.

T. Heusner, S. Kuemmel, A. Koeninger, 2010, Anticancer research.

Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment.

M. Beckmann, A. Schneeweiss, H. Tesch, 2010, Anticancer research.

c-erB-2 Onkogenexpression in Ovarialkarzinomen und Borderline-Tumoren

W. Lichtenegger, C. Minguillon, A. Reles, 1993, Archives of Gynecology and Obstetrics.

[Surgical abortion].

W. Lichtenegger, M. Lirmberger, 1979, Archives of gynecology.

Systematic Evaluation of the Intraoperative Tumor Pattern in Patients With Borderline Tumor of the Ovary

C. Denkert, W. Lichtenegger, J. Sehouli, 2009, International Journal of Gynecologic Cancer.

Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer

P. Neuhaus, W. Lichtenegger, J. Sehouli, 2010, Annals of Surgical Oncology.

Operative Results after Primary and Secondary Debulking‐Operations in Advanced Ovarian Cancer (AOC)

W. Lichtenegger, J. Sehouli, H. Weidemann, 1998, The journal of obstetrics and gynaecology research.

„IMO” - Intraoperatives Mapping des Ovarialkarzinoms

W. Lichtenegger, A. Mustea, J. Sehouli, 2003 .

["IMO"--intraoperative mapping of ovarian cancer].

W. Lichtenegger, D. Könsgen, A. Mustea, 2003, Zentralblatt fur Gynakologie.

Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.

M. Beckmann, P. Fasching, L. Häberle, 2021, JAMA oncology.

Multivisceral surgery for advanced gynaecological malignancies

S. Loening, P. Neuhaus, W. Lichtenegger, 2003, European Surgery.

Functional and anatomic results of amnion vaginoplasty in young women with Mayer-Rokitansky-Küster-Hauser syndrome.

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2010, Fertility and sterility.

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study

N. Haas, W. Lichtenegger, J. Sehouli, 2008, Supportive Care in Cancer.

Reconstructive surgical management of cryptomenorrhea because of complex uterovaginal malformations with duplicate uterus and complete vaginal agenesis.

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2010, Fertility and sterility.

Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report.

C. Denkert, M. Dietel, W. Henrich, 2006, Anticancer research.

Alpha-fetoprotein content of amniotic fluid in normal and abnormal pregnancies.

W. Lichtenegger, P. A. Weiss, P. Pürstner, 1978, Obstetrics and Gynecology.

Evaluation of CA 27.29 as Prognostic Marker in Primary Breast Cancer Patients – Results of the German SUCCESS Trial.

M. Beckmann, A. Schneeweiss, R. Kreienberg, 2009 .

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Tanja Fehm, Brigitte Rack, Matthias W. Beckmann, 2014, Journal of the National Cancer Institute.

The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer.

C. Denkert, W. Lichtenegger, J. Sehouli, 2006, Anticancer research.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

T. Bauknecht, I. Runnebaum, W. Lichtenegger, 2010, Cancer Chemotherapy and Pharmacology.

The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.

Maohui Luo, W. Lichtenegger, D. Könsgen, 2007, European journal of obstetrics, gynecology, and reproductive biology.

Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.

W. Lichtenegger, J. Sehouli, D. Könsgen, 2003, Anticancer research.

Primary Mucinous Adenocarcinoma of the Appendix: A Rare Entity in the Differential Diagnosis of Ovarian Cancer

H. Riess, W. Lichtenegger, D. Stengel, 2000, The journal of obstetrics and gynaecology research.

Expression and localization of e-cadherin in epithelial ovarian cancer.

E. Dahl, I. Klaman, W. Lichtenegger, 2010, Anticancer research.

Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO).

I. Vergote, W. Lichtenegger, D. Miller, 2013 .

[Mucinous metaplasia of fallopian tube mucous membrane as a cause of pseudomyxoma peritonei].

W. Friedmann, W. Lichtenegger, M. Vogel, 1992, Zentralblatt fur Pathologie.

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

R. Kreienberg, I. Runnebaum, A. Reles, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Correlation of p 53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer 1

R. Kreienberg, I. Runnebaum, A. Reles, 2001 .

Endometriotic cyst after subtotal abdominal hysterectomy mimicking carcinoma of the cervical stump

W. Henrich, A. Schmider, W. Lichtenegger, 2003, BJOG : an international journal of obstetrics and gynaecology.

NO‐donor nitroglycerin versus the prostaglandin gemeprost for cervical ripening in first trimester missed abortion

W. Lichtenegger, M. David, F.C.K. Chen, 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells

C. Denkert, W. Lichtenegger, J. Sehouli, 2005, Journal of Molecular Medicine.

The importance of parametrial lymph nodes in the treatment of cervical cancer

W. Lichtenegger, K. Tamussino, J. Haas, 1990, Gynecologic oncology.

Epidermal growth factor receptor changes during breast cancer metastasis.

W. Henrich, S. Kuemmel, A. Schmider, 2006, Anticancer research.

Expression of IL-10 in patients with ovarian carcinoma.

W. Lichtenegger, J. Sehouli, E. Braicu, 2006, Anticancer research.

Operative anatomy and technique of radical parametrial resection in the surgical treatment of cervical cancer.

W. Lichtenegger, G. Ralph, F. Anderhuber, 1988, Bailliere's clinical obstetrics and gynaecology.

Nitroglycerin to Facilitate Fetal Extraction During Cesarean Delivery

W. Lichtenegger, P. Sinha, T. Zimmermann, 1998, Obstetrics and gynecology.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.

C. Denkert, E. Dahl, I. Klaman, 2007, Gynecologic oncology.

Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer.

W. Lichtenegger, J. Sehouli, D. Koensgen, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer.

W. Lichtenegger, J. Sehouli, D. Könsgen, 2003, Anticancer research.

Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer.

W. Lichtenegger, J. Sehouli, D. Koensgen, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial.

Brigitte Rack, Matthias W. Beckmann, Andreas Schneeweiss, 2010 .

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

W. Lichtenegger, J. Sehouli, O. Camara, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Investigation of doxorubicin on the skin: A spectroscopic study to understand the pathogenesis of PPE

J. Blohmer, J. Lademann, M. Darvin, 2005 .

Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial.

M. Rezai, M. Beckmann, A. Schneeweiss, 2009 .

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study

M. Rezai, M. Lux, P. Fasching, 2014, Geburtshilfe und Frauenheilkunde.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilita

M. Beckmann, R. Kimmig, A. Meindl, 2018, Geburtshilfe und Frauenheilkunde.

Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany

C Denkert, C. Denkert, D. Boehmer, 2007, International Journal of Gynecologic Cancer.

Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2013, Cytokine.

Peripheral Neuroectodermal Tumor (PNET) of the Breast – a 6-Year Follow-Up

M. Dietel, J. Blohmer, S. Kümmel, 2006, Breast Care.

Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology

W. Lichtenegger, J. Sehouli, M. Zygmunt, 2016, International Journal of Gynecologic Cancer.

Urological complications after radical abdominal hysterectomy for cervical cancer.

W. Lichtenegger, G. Ralph, K. Tamussino, 1988, Bailliere's clinical obstetrics and gynaecology.

Relevance of sonographic criteria for differential diagnosis of mammary tumours

Rabih Chaoui, Gerd Schmalisch, R. Chaoui, 1997 .

Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

M. Beckmann, T. Fehm, A. Schneeweiss, 2018 .

Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.

M. Beckmann, P. Fasching, T. Fehm, 2018 .

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

M. Rezai, M. Beckmann, P. Fasching, 2018, Oncology Research and Treatment.

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity

M. Rezai, M. Lux, M. Beckmann, 2017, Oncotarget.

Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial

M. Beckmann, P. Fasching, T. Fehm, 2016 .

Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study

M. Rezai, M. Beckmann, L. Häberle, 2019, General Session Abstracts.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

M. Beckmann, R. Kimmig, A. Meindl, 2018, Geburtshilfe und Frauenheilkunde.

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

M. Stauch, H. Sommer, W. Lichtenegger, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer

W. Lichtenegger, J. Sehouli, P. Klare, 2004 .

Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer.

W. Lichtenegger, J. Sehouli, P. Klare, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.

R. Kimmig, S. Kuemmel, D. Boehmer, 2012 .

R. Kimmig, S. Kuemmel, D. Boehmer, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma.

A. Reles, A. Schmider, M. Press, 2000, Gynecologic oncology.

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

J. Blohmer, S. Kümmel, W. Lichtenegger, 2005, Acta oncologica.

Gestational Diabetes and Screening During Pregnancy

W. Lichtenegger, P. A. Weiss, P. Pürstner, 1984, Obstetrics and Gynecology.

Insulin Levels in Amniotic Fluid of Normal and Abnormal Pregnancies

W. Lichtenegger, P. A. Weiss, P. Pürstner, 1984, Obstetrics and gynecology.

The prognostic significance of epithelial-mesenchymal transition in breast cancer.

Wolfgang Henrich, H. Stein, W. Henrich, 2002, Anticancer research.

Diagnosis and treatment of gestational diabetes according to amniotic fluid insulin levels

W. Lichtenegger, J. Haas, P. Pürstner, 2005, Archives of gynecology.

Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.

S. Darb-Esfahani, W. Lichtenegger, J. Sehouli, 2010, Gynecologic oncology.

Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome

S. Kuemmel, I. Vergote, W. Cliby, 2022, International Journal of Gynecological Cancer.

Transvaginale Farbdopplersonographie in der präoperativen Diagnostik von Adnextumoren

W. Lichtenegger, U. Wein, M. Lübke, 1998 .

What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2010, Journal of psychosomatic obstetrics and gynaecology.

Urological complications after radical hysterectomy with or without radiotherapy for cervical cancer

W. Lichtenegger, G. Ralph, K. Tamussino, 2006, Archives of Gynecology and Obstetrics.

10 Operative anatomy and technique of radical parametrial resection in the surgical treatment of cervical cancer

W. Lichtenegger, G. Ralph, F. Anderhuber, 1988 .

Nitroglycerin application during cesarean delivery: plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns.

W. Lichtenegger, S. Veit, M. Walka, 2000, American journal of obstetrics and gynecology.

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.

W. Lehmacher, D. Wallwiener, G. von Minckwitz, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.

M. Beckmann, A. Schneeweiss, H. Sommer, 2012 .

Increased Incidence of Cervical Intraepithelial Neoplasia in Young Women in the Mitte District, Berlin, Germany

H. Guski, J. Blohmer, W. Lichtenegger, 1999, Acta Cytologica.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

Stefan Paepke, Diethelm Wallwiener, D. Wallwiener, 2008, BMC Cancer.

Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.

J. Blohmer, S. Kümmel, W. Lichtenegger, 2006, Critical reviews in oncology/hematology.

Insulin levels in amniotic fluid. Management of pregnancy in diabetes.

W. Lichtenegger, P. A. Weiss, P. Pürstner, 1978, Obstetrics and gynecology.

An estrogen receptor α-dependent regulation of estrogen receptor–related receptor α in the proliferation of endometrial carcinoma cells

W. Lichtenegger, J. Sehouli, D. Könsgen, 2006 .

Brain metastases from epithelial ovarian cancer: overview and optimal management.

Jalid Sehouli, D. Boehmer, W. Lichtenegger, 2009, Anticancer research.

Primary Radical Surgery in Elderly Patients With Epithelial Ovarian Cancer: Analysis of Surgical Outcome and Long-Term Survival

E. Steinhagen-Thiessen, W. Lichtenegger, J. Sehouli, 2009, International Journal of Gynecologic Cancer.

Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer

R. Felix, W. Lichtenegger, J. Sehouli, 2003, European Radiology.

301 Survival in Early Breast Cancer Patients is Influenced by Circulating Tumor Cells

M. Beckmann, A. Schneeweiss, H. Tesch, 2012 .

Value of preoperative transvaginal sonography (TVS) in the description of tumor pattern in ovarian cancer patients: results of a prospective study.

C. Denkert, W. Henrich, C. Wolf, 2007, Anticancer research.

Polymorphism of IL-1 receptor antagonist gene: role in cancer.

W. Lichtenegger, J. Sehouli, D. Könsgen, 2002, Anticancer research.

Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry.

A. Reles, A. Schmider, M. Press, 1998, Gynecologic oncology.

Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.

J. Blohmer, W. Lichtenegger, S. Paepke, 1999, Zentralblatt fur Gynakologie.

Safety and efficacy of first-line epirubicin-docetaxel (ED) versus epirubicin-cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC).

S. Kuemmel, J. Blohmer, W. Lichtenegger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Heart function in infants and small children, whose mothers required tocolysis with hexoprenaline sulfate (Gynipral)].

W. Lichtenegger, A. Beitzke, H. Rosegger, 1986, Wiener Klinische Wochenschrift.

Präoperative Diagnostik beim Ovarialkarzinom

W. Henrich, W. Lichtenegger, I. Braicu, 2006, Der Gynäkologe.

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO)

S. Loibl, W. Lichtenegger, J. Sehouli, 2007 .

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

R. Schmutzler, E. Wight, L. Kiesel, 2023, Geburtshilfe und Frauenheilkunde.

Comparison of the relaxation effect in vitro of nitroglycerin vs. fenoterol on human myometrial strips

W. Lichtenegger, C. Hamann, F. Chen, 2000, Journal of perinatal medicine.

Relapsed ovarian cancer after failure of first-line chemotherapy with platin and paclitaxel — a phase II study

W. Lichtenegger, J. Sehouli, D. Stengel, 2001 .

M. Rezai, A. Schneeweiss, H. Sommer, 2009 .

Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.

M. Stauch, H. Sommer, W. Lichtenegger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical outcome and survival analysis of young patients with primary epithelial ovarian cancer.

W. Lichtenegger, J. Sehouli, C. Fotopoulou, 2009, Anticancer research.

Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients

W. Lichtenegger, P. Nürnberg, J. Sehouli, 2007 .

Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients.

W. Lichtenegger, P. Nürnberg, J. Sehouli, 2007, Gynecologic Oncology.

Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study.

M. Rezai, M. Beckmann, P. Fasching, 2014 .

Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.

W. Lichtenegger, J. Sehouli, R. Richter, 2011, Anticancer research.

What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer.

P. Fasching, K. Münstedt, W. Lichtenegger, 2009, Journal of Clinical Oncology.

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO).

W. Lichtenegger, J. Sehouli, P. Harter, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

H. Sommer, W. Lichtenegger, J. Sehouli, 2008, Cancer Chemotherapy and Pharmacology.

[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study].

C. Denkert, R. Kimmig, J. Blohmer, 2008, Gynakologisch-geburtshilfliche Rundschau.

An estrogen receptor alpha-dependent regulation of estrogen receptor-related receptor alpha in the proliferation of endometrial carcinoma cells.

W. Lichtenegger, J. Sehouli, D. Könsgen, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.